Drug Watch
Compounds in Development for Chronic Hepatitis B
Updated July 6, 2020
FAMILY/DRUG NAME |
MECHANISM |
COMPANY |
WEBSITE |
|
|
Interferons: Mimic infection-fighting immune substances naturally produced in the body. |
||||
|
Intron A (Interferon alfa-2b) |
Immunomodulator |
Merck, USA |
Approved 1991 |
|
|
Pegasys (Peginterferon alfa-2a) |
Immunomodulator |
Genentech, USA |
Approved 2005 |
|
|
|
||||
|
Epivir (Lamivudine) |
Inhibits viral DNA polymerase |
GlaxoSmithKline (GSK) |
Approved 1998 |
|
|
Hepsera (Adefovir dipivoxil) |
Inhibits viral DNA polymerase |
Gilead Sciences, USA |
Approved 2002 |
|
|
Baraclude (Entecavir) |
Inhibits viral DNA polymerase |
Bristol-Myers Squibb, USA |
Approved 2005 |
|
|
Tyzeka (Telbivudine) |
Inhibits viral DNA polymerase |
Novartis, USA |
||
|
Viread (Tenofovir) |
Inhibits viral DNA polymerase |
Gilead Sciences |
Approved 2008 |
|
|
Vemlidy (TAF or tenofovir alafenamide) |
Prodrug of tenofovir |
Gilead Sciences |
Approved 2016 |
|
|
Levovir (Clevudine) |
Inhibits viral DNA polymerase |
Bukwang, S. Korea |
Approved 2006 in S. Korea |
|
|
Besivo (formerly ANA 380/LB80380) |
Inhibits viral DNA polymerase |
Ildong Pharma, S. Korea |
Approved 2017 in S. Korea |
|
|
Zadaxin |
Immunomodulator |
SciClone, USA |
Approved outside USA |
|
|
DIRECT ACTING ANTIVIRALS: Targets the virus and interferes in the HBV replication process |
||||
|
Silencing RNA’s (siRNAs): Interferes and destroys viral RNA |
||||
|
VIR-2218 |
RNAi gene silencer |
Alnylam and Vir Biotech, USA |
Phase II |
|
|
RG6346 (DCR HBVS) |
RNAi gene silencer |
Roche, Switzerland |
Phase I/II |
|
|
ARO-HBV |
RNAi gene silencer |
Arrowhead Pharma with Janssen, USA |
Phase I/II | |
|
AB-729 |
RNAi gene silencer |
Arbutus Biopharma, USA |
Phase I | |
|
BB-103 |
RNAi gene silencer |
Benitec, Australia |
Preclinical |
|
|
Lunar-HBV |
RNAi gene silencer |
Arcturus with Janssen, USA |
Preclinical |
|
|
Entry Inhibitors: Interferes with HBV getting into liver cells |
||||
|
Hepcludex (Bulevirtide formerly Myrcludex B) |
Entry inhibitor |
Hepatera, Russia with MYR GmbH, Germany |
Phase II |
|
|
Capsid or Core Inhibitors: Interferes with the viral DNA protein shield |
||||
|
Morphothiadin |
Capsid inhibitor |
HEC Pharma, |
Phase II |
|
|
JNJ 56136379 |
Capsid inhibitor |
Janssen, Ireland |
Phase II |
|
|
ABI-H0731 |
Capsid inhibitor |
Assembly Biosciences, USA |
Phase II |
|
|
ABI-H2158 |
Capsid inhibitor |
Assembly Biosciences, USA |
Phase II | |
|
RG7907 |
Capsid inhibitor |
Roche, Switzerland |
Phase I | |
|
QL-007 |
Capsid inhibitor |
Qilu, PR China |
Phase I | |
|
EDP-514 |
Capsid inhibitor |
Enanta Pharma, USA |
Phase I | |
|
ABI-H3733 |
Capsid inhibitor |
Assembly Biosciences, USA |
Phase I | |
|
ZM-H1505R |
Capsid inhibitor |
ZhiMeng Biopharma, PR China |
Phase I | |
|
GLP-26 |
Capsid inhibitor |
Emory University, USA |
Preclinical | |
|
ALG-000184 |
Capsid inhibitor |
Aligos Therapeutics, USA |
Preclinical | |
|
HBsAg Inhibitors: Interferes with production of HBV surface antigen (sAg) |
||||
|
REP 2139 |
sAg inhibitor |
Replicor, Canada |
Phase II |
|
|
REP 2165 |
sAg inhibitor |
Replicor, Canada |
Phase II |
|
|
ALG-10133 |
STOPs (s-Antigen transport inhibiting oligonucleotide polymers) |
Aligos Therapeutics, USA |
Preclinical | |
|
Antisense Molecules: Binds to the viral mRNA to prevent it from turning into viral protein |
||||
|
GSK 3228836 (IONIS-HBVRx) |
Prevent viral protein production |
Ionis with GSK, USA |
Phase II |
|
|
ALG-020572/020576 |
Prevent viral protein production |
Aligos Therapeutics, USA |
Preclinical | |
|
INDIRECT ACTING ANTIVIRALS: Targets the human immune system to attack the HBV virus |
||||
|
Therapeutic Vaccines: Vaccine technology used to stimulate the immune system as a treatment |
||||
|
HepTcell |
Therapeutic vaccine |
Altimmune, USA |
Phase II |
|
|
AIC 649 |
Therapeutic vaccine |
AiCuris, Germany |
Phase I |
|
|
INO-1800 |
Therapeutic vaccine |
Inovio, USA |
Phase I |
|
|
HB-110 |
Therapeutic vaccine |
Ichor Medical Genexine, USA |
||
|
TG1050 |
Therapeutic vaccine |
Transgene, France |
Phase I | |
|
VTP-300 |
Therapeutic vaccine |
Vaccitech, USA |
Phase I |
|
|
JNJ 64300535 |
Therapeutic vaccine |
Janssen, Ireland |
Preclinical |
|
|
HBV |
Therapeutic vaccine |
GeoVax, USA |
Preclinical |
|
|
VBI-2601 |
Therapeutic vaccine |
VBI Vaccines, USA |
vbivaccines.com | Preclinical |
|
Chimigen HBV |
Therapeutic vaccine |
Akshaya, Canada |
akshayabio.com | Preclinical |
|
CARG-201 |
Therapeutic vaccine |
CaroGen, USA |
carogencorp.com | Preclinical |
|
HBV |
Therapeutic vaccine |
HOOKIPA Pharma, Austria, with Gilead |
hookipapharma.com/ | Preclinical |
|
TherVacB |
Therapeutic vaccine |
Helmholtz Zentrum Muenchen, Germany |
dzif.de/en/hepatitis | Preclinical |
|
Innate Immune Defense Pathway: Compounds that activate the innate immune system |
||||
|
GS9688 |
TLR-8 agonist |
Gilead Sciences, USA |
Phase I |
|
|
RG7854 |
TLR-7 agonist |
Roche, Switzerland |
Phase I | |
|
Host Acting Pathway: Compounds that target cell functions needed by the hepatitis B virus |
||||
|
APG-1387 |
Apoptosis Inducer |
Ascentage Pharma, PR China |
Phase II |
|
|
CRV 431 |
Ciclofillin inhibitor |
Hepion, USA (formerly ContraVir) |
Phase I |
|
|
Gene Editing |
||||
|
EBT106 |
CRISPR/Cas 9 | Excision Bio, USA | excisionbio.com | Preclinical |
|
HBV |
ARCUS platform | Precision Bio with Gilead, USA | precisionsciences.com | Preclinical |
|
|
||||
|
GC1102 |
monoclonal anti-HBsAg antibody | Green Cross, South Korea | globalgreencross.com | Phase II |
|
EYP001 |
FXR agonist | Enyo Pharma, France | enyopharma.com | Phase I |
|
RG6084 |
Host targeting antisense (LNA) | Roche, Switzerland | roche.com | Phase I |
|
RG6217 |
Host targeting antisense (LNA) | Roche, Switzerland | roche.com | Phase I |
|
ASC22 (KN035) |
PD-L1 | Ascletis Pharma, PR China | ascletis.com | Phase I |
|
LTCR-H2-1 |
T Cell immunotherapy | Lion TCR, Singapore | liontcr.com | Preclinical |
|
HBV |
MicroRNA | Regulus, USA | regulusrx.com | Preclinical |
|
ENOB-HB-01 |
Nucleic Acid-directed HBV cell killing | Enochian BioSciences, USA | enochianbio.com | Preclinical |
|
GV1001 |
"Novel peptide" | GenVax & KAEL, South Korea | gemvax.com | Preclinical |
|
CP101 |
Oral microbiotic | Finch Therapeutics, USA | finchtherapeutics.com | Preclinical |
|
HEPATITIS DELTA VIRUS (HDV)- A virus that co-infects people already infected with HBV |
||||
|
Hepcludex (Bulevirtide formerly Myrcludex B) |
Entry inhibitor |
MYR-GmbH, Germany |
Phase III |
|
|
Lonafarnib |
Prenylation inhibitor |
Eiger Biopharma, USA |
Orphan drug |
|
|
REP 2139 |
HBsAg inhibitor |
Replicor, Canada |
Phase II |
|
|
Ezetimibe |
NTCP inhibitor |
Ziauddin University Hospital, Pakistan |
Phase II |
|
|
GI-18000 |
Immune Response Stimulator |
GlobeImmune |
Preclinical |
|